Q2 2025 Amphastar Pharmaceuticals Inc Earnings Call Transcript

Aug 7, 2025 / 09:00 PM GMT

Release Date Price: $21.62 (+3.84%)

Transcript 10-Q8-K

Key Points

Positve

Amphastar Pharmaceuticals Inc (AMPH) reported strong net revenues of $174.4 million and a GAAP net income of $31 million for Q2 2025.
The company's vaccine sales increased by 21% year over year, driven by successful global commercialization and higher average selling prices.
Amphastar is expanding its California headquarters to quadruple domestic manufacturing capacity, enhancing operational resilience and supporting R&D pipeline advancement.
The company is optimistic about near-term FDA approval for its product candidate AMP 002, following productive discussions with the agency.
Amphastar is well-positioned to benefit from the growing market for interchangeable insulin biosimilars, with a focus on developing high-quality complex injectables.

Negative

Revenues for the second quarter decreased by 4% compared to the previous year, impacted by increased competition in legacy products.
Gross margins declined to 49.6% from 52.2% due to pricing declines and increased competition for certain products.
Epinephrine sales decreased by 42% due to increased competition and the return of another supplier to the market.
Glucagon injection sales declined by 25% due to increased competition and a shift towards ready-to-use products.
The company expects continued price competition and margin contraction for certain products, impacting future financial performance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AMPH.OQ - Amphastar Pharmaceuticals Inc
Q2 2025 Amphastar Pharmaceuticals Inc Earnings Call
Aug 07, 2025 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the Amphastar Pharmaceuticals 2nd quarter earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press 0 on your telephone keypad keypad.

Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions for future periods are forward-looking statements.

These statements are based solely on information that is now available to us. We encourage you to review the session entitled forward-looking Statements in the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.